Global GLP-1 Receptor Agonist Industry, propelled by the rising diabetes epidemic, is anticipated to exceed US$ 11.24 Billion by 2032, according to FMI
Future Market Insights, a leading player in the pharmaceutical industry, anticipates substantial growth in the